Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Open Forum Infectious Diseases|December 18, 2019
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive InfectionsMark Redell, Miguel Sierra-Hoffman, Maha Assi, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 25, 2025
Epidemiology, length of stay, and survival outcomes of Candida auris infections in a tertiary care center in the greater detroit areaHussein Tehaili, Shayan Sharifi, Sruti Ramamoorthy, et al.
Frontiers in Medicine|August 15, 2022
It's about the patients: Practical antibiotic stewardship in outpatient settings in the United StatesAlpesh N Amin, E Patchen Dellinger, Glenn Harnett, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Open Forum Infectious Diseases|April 6, 2026
Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized TrialsLuis Ostrosky-Zeichner, Jalal A Aram, Mark Redell, et al.
Journal of Clinical Gastroenterology|November 29, 2023
Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3Paul Feuerstadt, Carl V Crawford, Xing Tan, et al.
Clinical Orthopaedics and Related Research|March 19, 2025
Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium?Martin Krsak, Taylor Morrisette, Laura Damioli, et al.
Infectious Diseases and Therapy|January 18, 2024
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile InfectionPaul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, et al.
The Lancet. Infectious Diseases|January 25, 2026
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled studyThomas Louie, Wendy Ribble, Louis Boccumini, et al.
Pageof 6